RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report

Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While RET fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with TRIM33-RET fusion has not been previously reported. Herein, we presented a case of a 68-year...

全面介紹

書目詳細資料

Principais autores:	Tongyi Zhang, Hongwei Wang, Zhiwei Cai, Siqi Zhang, Chongyi Jiang
格式:	Artigo
語言:	Inglês
出版:	Frontiers Media S.A. 2023-04-01
叢編:	Frontiers in Oncology
主題:	pancreatic cancer RET fusion pralsetinib target therapy RET inhibitors
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1078076/full
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!